+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Duchenne Muscular Dystrophy Drugs - Market Analysis, Trends, and Forecasts

  • ID: 4804175
  • Report
  • 94 pages
  • Global Industry Analysts, Inc
1 of 3

FEATURED COMPANIES

  • Acceleron Pharma
  • Biomarin Pharmaceutical
  • Janssen Pharmaceuticals
  • Nippon Shokubai
  • Pfizer
  • Sarepta Therapeutics
  • MORE
The Duchenne Muscular Dystrophy Drugs market worldwide is projected to grow by US$4.9 Billion, driven by a compounded growth of 40.5%. Mutation Suppression, one of the segments analyzed and sized in this study, displays the potential to grow at over 39%. The shifting dynamics supporting this growth makes it critical for businesses in this space to keep abreast of the changing pulse of the market. Poised to reach over US$1.9 Billion by the year 2025, Mutation Suppression will bring in healthy gains adding significant momentum to global growth.

Representing the developed world, the United States will maintain a 45% growth momentum. Within Europe, which continues to remain an important element in the world economy, Germany will add over US$141.4 Million to the region's size and clout in the next 5 to 6 years. Over US$226.5 Million worth of projected demand in the region will come from the rest of the European markets. In Japan, Mutation Suppression will reach a market size of US$144.6 Million by the close of the analysis period. As the world’s second largest economy and the new game changer in global markets, China exhibits the potential to grow at 38.9% over the next couple of years and add approximately US$809.3 Million in terms of addressable opportunity for the picking by aspiring businesses and their astute leaders.

Presented in visually rich graphics are these and many more need-to-know quantitative data important in ensuring quality of strategy decisions, be it entry into new markets or allocation of resources within a portfolio. Several macroeconomic factors and internal market forces will shape growth and development of demand patterns in emerging countries in Asia-Pacific. All research viewpoints presented are based on validated engagements from influencers in the market, whose opinions supersede all other research methodologies.

Competitors identified in this market include:
  • Acceleron Pharma, Inc.
  • Akashi Therapeutics, Inc.
  • BioMarin Pharmaceutical, Inc.
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • Janssen Pharmaceuticals, Inc.
  • Lexicon Pharmaceuticals, Inc.
  • Nippon Shokubai Co., Ltd.
  • Nobelpharma Co., Ltd.
  • Pfizer, Inc.
  • PTC Therapeutics, Inc.
  • Sarepta Therapeutics Inc.
  • Taiho Pharmaceutical Co., Ltd.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Acceleron Pharma
  • Biomarin Pharmaceutical
  • Janssen Pharmaceuticals
  • Nippon Shokubai
  • Pfizer
  • Sarepta Therapeutics
  • MORE

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

Duchenne Muscular Dystrophy (DMD) Drugs Market To Exhibit Strong Growth

Global Competitor Market Shares

Duchenne Muscular Dystrophy Drugs Competitor Market Share Scenario Worldwide (in %): 2019 & 2025

Global Market Dynamics

Treatment Overview and Recent Developments

Steroids used for the Treatment of DMD

Translarna Exhibits Positive Result in Children with DMD

Clinical Trials Depict Emflaza Preserves Motor Function Better than Corticosteroids

Trial Shows Golodirsen Increases Dystrophin Production in DMD Patients

Casimersen and Golodirsen Exhibits Positive Results in Sarepta’s ESSENCE study

EXONDYS 51® Drug Details

FDA Approves Corticosteroid Emflaza for Treating DMD Patients

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

Pipeline Analysis

Drug Price Details: Exondys51

Sarepta’s DMD Gene Therapy Trial Update

4. GLOBAL MARKET PERSPECTIVE

TABLE 1: Duchenne Muscular Dystrophy Drugs Global Market Estimates and Forecasts in US$ Thousand by Region/Country: 2018-2025

TABLE 2: Duchenne Muscular Dystrophy Drugs Global Retrospective Market Scenario in US$ Thousand by Region/Country: 2009-2017

TABLE 3: Duchenne Muscular Dystrophy Drugs Market Share Shift across Key Geographies Worldwide: 2009 VS 2019 VS 2025

TABLE 4: Mutation Suppression (Segment) World Market by Region/Country in US$ Thousand: 2018 to 2025

TABLE 5: Mutation Suppression (Segment) Historic Market Analysis by Region/Country in US$ Thousand: 2009 to 2017

TABLE 6: Mutation Suppression (Segment) Market Share Breakdown of Worldwide Sales by Region/Country: 2009 VS 2019 VS 2025

TABLE 7: Exon Skipping (Segment) Potential Growth Markets Worldwide in US$ Thousand: 2018 to 2025

TABLE 8: Exon Skipping (Segment) Historic Market Perspective by Region/Country in US$ Thousand: 2009 to 2017

TABLE 9: Exon Skipping (Segment) Market Sales Breakdown by Region/Country in Percentage: 2009 VS 2019 VS 2025

TABLE 10: Other Segments (Segment) Geographic Market Spread Worldwide in US$ Thousand: 2018 to 2025

TABLE 11: Other Segments (Segment) Region Wise Breakdown of Global Historic Demand in US$ Thousand: 2009 to 2017

TABLE 12: Other Segments (Segment) Market Share Distribution in Percentage by Region/Country: 2009 VS 2019 VS 2025

III. MARKET ANALYSIS

GEOGRAPHIC MARKET ANALYSIS

UNITED STATES

Market Facts & Figures

US Duchenne Muscular Dystrophy Drugs Market Share (in %) by Company: 2019 & 2025

TABLE 13: United States Duchenne Muscular Dystrophy Drugs Market Estimates and Projections in US$ Thousand by Segment: 2018 to 2025

TABLE 14: Duchenne Muscular Dystrophy Drugs Market in the United States by Segment: A Historic Review in US$ Thousand for 2009-2017

TABLE 15: United States Duchenne Muscular Dystrophy Drugs Market Share Breakdown by Segment: 2009 VS 2019 VS 2025

CANADA

TABLE 16: Canadian Duchenne Muscular Dystrophy Drugs Market Estimates and Forecasts in US$ Thousand by Segment: 2018 to 2025

TABLE 17: Canadian Duchenne Muscular Dystrophy Drugs Historic Market Review by Segment in US$ Thousand: 2009-2017

TABLE 18: Duchenne Muscular Dystrophy Drugs Market in Canada: Percentage Share Breakdown of Sales by Segment for 2009, 2019, and 2025

JAPAN

TABLE 19: Japanese Market for Duchenne Muscular Dystrophy Drugs: Annual Sales Estimates and Projections in US$ Thousand by Segment for the Period 2018-2025

TABLE 20: Duchenne Muscular Dystrophy Drugs Market in Japan: Historic Sales Analysis in US$ Thousand by Segment for the Period 2009-2017

TABLE 21: Japanese Duchenne Muscular Dystrophy Drugs Market Share Analysis by Segment: 2009 VS 2019 VS 2025

CHINA

TABLE 22: Chinese Duchenne Muscular Dystrophy Drugs Market Growth Prospects in US$ Thousand by Segment for the Period 2018-2025

TABLE 23: Duchenne Muscular Dystrophy Drugs Historic Market Analysis in China in US$ Thousand by Segment: 2009-2017

TABLE 24: Chinese Duchenne Muscular Dystrophy Drugs Market by Segment: Percentage Breakdown of Sales for 2009, 2019, and 2025

EUROPE

Market Facts & Figures

European Duchenne Muscular Dystrophy Drugs Market: Competitor Market Share Scenario (in %) for 2019 & 2025

Irish Boys with nonsense mutation Duchenne muscular dystrophy (nmDMD) Gains Access to Key, Life-Supporting Drug

CHMP Rejects Exondys 51 in Europe

TABLE 25: European Duchenne Muscular Dystrophy Drugs Market Demand Scenario in US$ Thousand by Region/Country: 2018-2025

TABLE 26: Duchenne Muscular Dystrophy Drugs Market in Europe: A Historic Market Perspective in US$ Thousand by Region/Country for the Period 2009-2017

TABLE 27: European Duchenne Muscular Dystrophy Drugs Market Share Shift by Region/Country: 2009 VS 2019 VS 2025

TABLE 28: European Duchenne Muscular Dystrophy Drugs Market Estimates and Forecasts in US$ Thousand by Segment: 2018-2025

TABLE 29: Duchenne Muscular Dystrophy Drugs Market in Europe in US$ Thousand by Segment: A Historic Review for the Period 2009-2017

TABLE 30: European Duchenne Muscular Dystrophy Drugs Market Share Breakdown by Segment: 2009 VS 2019 VS 2025

FRANCE

TABLE 31: Duchenne Muscular Dystrophy Drugs Market in France by Segment: Estimates and Projections in US$ Thousand for the Period 2018-2025

TABLE 32: French Duchenne Muscular Dystrophy Drugs Historic Market Scenario in US$ Thousand by Segment: 2009-2017

TABLE 33: French Duchenne Muscular Dystrophy Drugs Market Share Analysis by Segment: 2009 VS 2019 VS 2025

GERMANY

TABLE 34: Duchenne Muscular Dystrophy Drugs Market in Germany: Recent Past, Current and Future Analysis in US$ Thousand by Segment for the Period 2018-2025

TABLE 35: German Duchenne Muscular Dystrophy Drugs Historic Market Analysis in US$ Thousand by Segment: 2009-2017

TABLE 36: German Duchenne Muscular Dystrophy Drugs Market Share Breakdown by Segment: 2009 VS 2019 VS 2025

ITALY

TABLE 37: Italian Duchenne Muscular Dystrophy Drugs Market Growth Prospects in US$ Thousand by Segment for the Period 2018-2025

TABLE 38: Duchenne Muscular Dystrophy Drugs Historic Market Analysis in Italy in US$ Thousand by Segment: 2009-2017

TABLE 39: Italian Duchenne Muscular Dystrophy Drugs Market by Segment: Percentage Breakdown of Sales for 2009, 2019, and 2025

UNITED KINGDOM

TABLE 40: United Kingdom Market for Duchenne Muscular Dystrophy Drugs: Annual Sales Estimates and Projections in US$ Thousand by Segment for the Period 2018-2025

TABLE 41: Duchenne Muscular Dystrophy Drugs Market in the United Kingdom: Historic Sales Analysis in US$ Thousand by Segment for the Period 2009-2017

TABLE 42: United Kingdom Duchenne Muscular Dystrophy Drugs Market Share Analysis by Segment: 2009 VS 2019 VS 2025

REST OF EUROPE

TABLE 43: Rest of Europe Duchenne Muscular Dystrophy Drugs Market Estimates and Forecasts in US$ Thousand by Segment: 2018-2025

TABLE 44: Duchenne Muscular Dystrophy Drugs Market in Rest of Europe in US$ Thousand by Segment: A Historic Review for the Period 2009-2017

TABLE 45: Rest of Europe Duchenne Muscular Dystrophy Drugs Market Share Breakdown by Segment: 2009 VS 2019 VS 2025

ASIA-PACIFIC

TABLE 46: Duchenne Muscular Dystrophy Drugs Market in Asia-Pacific by Segment: Estimates and Projections in US$ Thousand for the Period 2018-2025

TABLE 47: Asia-Pacific Duchenne Muscular Dystrophy Drugs Historic Market Scenario in US$ Thousand by Segment: 2009-2017

TABLE 48: Asia-Pacific Duchenne Muscular Dystrophy Drugs Market Share Analysis by Segment: 2009 VS 2019 VS 2025

REST OF WORLD

TABLE 49: Rest of World Duchenne Muscular Dystrophy Drugs Market Estimates and Forecasts in US$ Thousand by Segment: 2018 to 2025

TABLE 50: Rest of World Duchenne Muscular Dystrophy Drugs Historic Market Review by Segment in US$ Thousand: 2009-2017

TABLE 51: Duchenne Muscular Dystrophy Drugs Market in Rest of World: Percentage Share Breakdown of Sales by Segment for 2009, 2019, and 2025

IV. COMPETITION

ACCELERON PHARMA

AKASHI THERAPEUTICS

BIOMARIN PHARMACEUTICAL

BRISTOL-MYERS SQUIBB COMPANY

ELI LILLY AND COMPANY

JANSSEN PHARMACEUTICALS

LEXICON PHARMACEUTICALS

NIPPON SHOKUBAI

NOBELPHARMA

PTC THERAPEUTICS

PFIZER

SAREPTA THERAPEUTICS

TAIHO PHARMACEUTICAL

V. CURATED RESEARCH

Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Acceleron Pharma
  • Akashi Therapeutics
  • Biomarin Pharmaceutical
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • Janssen Pharmaceuticals
  • Lexicon Pharmaceuticals
  • Nippon Shokubai
  • Nobelpharma
  • Ptc Therapeutics
  • Pfizer
  • Sarepta Therapeutics
  • Taiho Pharmaceutical
Note: Product cover images may vary from those shown
Adroll
adroll